Clinical guidance on pharmacotherapy for the treatment of attention-deficit hyperactivity disorder (ADHD) for people with intellectual disability

References

• Strømme P, Diseth T. Prevalence of psychiatric diagnoses in children with mental retardation: data from a population-based study. Dev Med Child Neurol. 2000;42(4):266–270.
   PubMed Web of Science ®Google Scholar
• Emerson E. Prevalence of psychiatric disorders in children and adolescents with and without intellectual disability. J Intellectual Disability Res. 2003;47(1):51–58.
   PubMed Web of Science ®Google Scholar
• Barkley RA. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. 3rd ed. New York: Guilford Press; 2006.
   Google Scholar
• La Malfa G, Lassi S, Bertelli M, et al. Detecting attention-deficit/hyperactivity disorder (ADHD) in adults with intellectual disability. Res Dev Disabil. 2008;29(2):158–164.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed ed. Arlington (VA): American Psychiatric Association; 2013.
   Google Scholar
• Maulik P, Mascarenhas M, Mathers CD, et al. Prevalence of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil. 2011 March;32(2):419–436. .
   PubMed Web of Science ®Google Scholar
• Hughes-McCormack L, Rydzewska E, Henderson A, et al. Prevalence of mental health conditions and relationship with general health in a whole-country population of people with intellectual disabilities compared with the general population. BJPsych Open. 2017;3(5):243–248.
   PubMed Web of Science ®Google Scholar
• Cooper S, Smiley E, Morrison J, et al. Mental ill-health in adults with intellectual disabilities: prevalence and associated factors. Br J Psychiatry. 2007;190(1):27–35.
   PubMed Web of Science ®Google Scholar
• Ettinger A, Ottman R, Lipton R, et al. Attention-deficit/hyperactivity disorder symptoms in adults with self-reported epilepsy: results from a national epidemiologic survey of epilepsy. Epilepsia. 2015;56(2):218–224.
   PubMed Web of Science ®Google Scholar
• Al‐Khudairi R, Perera B, Solomou S, et al. Adults with intellectual disability and attention deficit hyperactivity disorder: clinical characteristics and medication profiles. Br J Learn Disabil. 2019;47(2):145–152.
   Web of Science ®Google Scholar
• Magon R, Müller U. ADHD with comorbid substance use disorder: review of treatment. Adv Psychiatric Treat. 2012;18(6):436–446.
   Google Scholar
• Mannuzza S, Klein R, Moulton J. Lifetime criminality among boys with attention deficit hyperactivity disorder: A prospective follow-up study into adulthood using official arrest records. Psychiatry Res. 2008;160(3):237–246.
   PubMed Web of Science ®Google Scholar
• Jacob C, Romanos J, Dempfle A, et al. Co-morbidity of adult attention-deficit/hyperactivity disorder with focus on personality traits and related disorders in a tertiary referral centre. Eur Arch Psychiatry Clin Neurosci. 2007;257(6):309–317. .
   PubMed Web of Science ®Google Scholar
• Lichtenstein P, Halldner L, Zetterqvist J, et al. Medication for attention deficit–hyperactivity disorder and criminality. N Engl J Med. 2012;367(21):2006–2014. .
   PubMed Web of Science ®Google Scholar
• Perera B. Attention Deficit Hyperactivity Disorder in people with Intellectual Disability. Ir J Psychol Med. 2018;35(3):213–219.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE guidelines; London. 2018.
   Google Scholar
• Chan E, Fogler J, Hammerness P. Treatment of attention-deficit/hyperactivity disorder in adolescents. JAMA. 2016;315(18):1997.
   PubMed Web of Science ®Google Scholar
• Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738. .
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–341. .
   PubMed Web of Science ®Google Scholar
• Jou R, Handen B, Hardan A. Psychostimulant treatment of adults with mental retardation and attention-deficit hyperactivity disorder. Australas Psychiatry. 2004;12(4):376–379.
   PubMedGoogle Scholar
• Aman MG, Singh N, Stewart A, et al. Psychometric characteristics of the aberrant behavior checklist. Am J Mental Deficiency. 1985;89(5):492–502.
   PubMedGoogle Scholar
• Aman MG, Pearson DA. Monitoring and measuring drug effects, II: behavioral, emotional, and cognitive effects. In: Werry JS, Aman MG, editors. The practitioner’s guide to psychoactive drugs for children and adolescents. 2nd ed. Plenum Medical Book Library, New York; 1999. pp 99-164.
   Google Scholar
• Conners CK, Sitarenios G, Parker JD, et al. Revision and restandardization of the Conners teacher rating scale (CTRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26(4):279–291.
   PubMed Web of Science ®Google Scholar
• Conners CK, Sitarenios G, Parker JD, et al. The revised Conners’ parent rating scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26(4):257–268.
   PubMed Web of Science ®Google Scholar
• Swanson JM. School-Based Assessment and Interventions for ADD Students. Irvine, CA: KC Publications; 1992.
   Google Scholar
• Ullmann R, Sleator E. Attention deficit disorder children with or without hyperactivity. Clin Pediatr (Phila). 1985;24(10):547–551.
   PubMed Web of Science ®Google Scholar
• Conners CK. Conners’ abbreviated symptom questionnaire manual. North Tonawanda, NY: Multi-Health Systems; 1990.
   Google Scholar
• Goyette CH, Conners CK, Ulrich RF. Normative data on revised Conners parent and teacher rating scales. J Abnormal Child Psychol. 1978;6(2):221–236.
   PubMed Web of Science ®Google Scholar
• Conners CK. Conners’ continuous performance test. Toronto, Ontario, Canada: Multi-Health Systems; 1995.
   Google Scholar
• Quay H, Peterson D. Manual for the revised behavior problem checklist. Coral Gables FL: University of Miami; 1987.
   Google Scholar
• Aman MG. The nisonger CBRF: A child behavior rating form for children with developmental disabilities. Res Dev Disabil. 1996;17(1):41–57.
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: U.S. DHEW, NIMH; 1976. (NIMH Publication No. 76–338).
   Google Scholar
• Tarrant N, Roy M, Deb S, et al. The effectiveness of methylphenidate in the management of attention deficit hyperactivity disorder (ADHD) in people with intellectual disabilities: a systematic review. Res Dev Disabil. 2018;83:217–232. .
   PubMed Web of Science ®Google Scholar
• Sun C, Tseng P, Wu C, et al. Therapeutic effects of methylphenidate for attention-deficit/hyperactivity disorder in children with borderline intellectual functioning or intellectual disability: A systematic review and meta-analysis. Sci Rep. 2019; 9(1):15908
   Google Scholar
• Simonoff E, Taylor E, Baird G, et al. Randomized controlled double‐blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. J Child Psychol Psychiatry. 2013;54(5):527–535. .
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. Abingdon: Routledge; 1988.
   Google Scholar
• Aman MG, Kern RA, McGhee DE, et al. Fenfluramine and methylphenidate in children with mental retardation and ADHD: clinical and Side Effects. J Am Academy Child Adolesc Psychopharmacol. 1993;32(4):851–859.
   PubMed Web of Science ®Google Scholar
• Hagerman R, Murphy M, Wittenberger M. A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet A. 1988;30(1–2):377–392.
   Web of Science ®Google Scholar
• MG A, Marks R, Turbott S, et al. Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. J Am Acad Child Adolesc Psychiatry. 1991;30(2):246–256.
   PubMed Web of Science ®Google Scholar
• Aman MG, Marks R, Turbott S, et al. Methylphenidate and thioridazine in the treatment of intellectually subaverage children. J Am Acad Child Adolesc Psychiatry. 1991;30(5):816–824.
   PubMed Web of Science ®Google Scholar
• Pearson D, Santos C, Casat C, et al. Treatment effects of methylphenidate on cognitive functioning in children with mental retardation and ADHD. J Am Acad Child Adolesc Psychiatry. 2004;43(6):677–685. .
   PubMed Web of Science ®Google Scholar
• Pearson DA, Santos CW, Roache JD, et al. Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD. J Am Acad Child Adolesc Psychiatry. 2003Feb1;42(2):209–216.
   PubMed Web of Science ®Google Scholar
• Handen B, McAuliffe S, Caro-Martinez L. Learning effects of methylphenidate in children with mental retardation. J Dev Phys Disability. 1996;8(4):335–346.
   Web of Science ®Google Scholar
• Handen B, Sagady A, McAuliffe-Bellin S. Methylphenidate and play skills in children with intellectual disability and ADHD. J Mental Health Res Intellectual Disabilities. 2009;2(1):1–10.
   Web of Science ®Google Scholar
• Aman MG, Singh N. Methylphenidate in severely retarded residents and the clinical significance of stereotypic behavior. Appl Res Mental Retardation. 1982;3(4):345–358.
   PubMedGoogle Scholar
• Aman M, Buican B, Arnold L. Methylphenidate treatment in children with borderline IQ and mental retardation: analysis of three aggregated studies. J Child Adolesc Psychopharmacol. 2003;13(1):29–40.
   PubMed Web of Science ®Google Scholar
• Pearson D, Lane D, Santos C, et al. Effects of methylphenidate treatment in children with mental retardation and ADHD: individual variation in medication response. J Am Acad Child Adolesc Psychiatry. 2004;43(6): 686–698.
   PubMed Web of Science ®Google Scholar
• Correia Filho A, Bodanese R, Silva T, et al. Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation. J Am Acad Child Adolesc Psychiatry. 2005;44(8):748–755.
   PubMed Web of Science ®Google Scholar
• Fosi T, Lax-Pericall M, Scott R, et al. Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: evidence of clinical benefit. Epilepsia. 2013;54(12):2071–2081.
   PubMed Web of Science ®Google Scholar
• Green T, Avda S, Dotan I, et al. Phenotypic psychiatric characterization of children with Williams syndrome and response of those with ADHD to methylphenidate treatment. Am J Med Genet B Neuropsychiatr Genet. 2011;159B(1):13–20.
   PubMed Web of Science ®Google Scholar
• Green T, Weinberger R, Diamond A, et al. The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome. J Child Adolesc Psychopharmacol. 2011;21(6):589–595.
   PubMed Web of Science ®Google Scholar
• Gothelf D, Gruber R, Presburger G, et al. Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome. J Clin Psychiatry. 2003;64(10):1163–1169.
   PubMed Web of Science ®Google Scholar
• Faraone SV. The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018 1;87:255–270.
   PubMed Web of Science ®Google Scholar
• Castells X, Ramos-Quiroga J, Bosch R, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2011. DOI:10.1002/14651858.CD007813.pub2
   PubMed Web of Science ®Google Scholar
• Fernández-Jaén A, Fernández-Mayoralas D, Calleja Pérez B, et al. Atomoxetine for attention deficit hyperactivity disorder in mental retardation. Pediatr Neurol. 2010;43(5):341–347. .
   PubMed Web of Science ®Google Scholar
• Fernández-Jaén A, Fernández-Mayoralas D, Calleja-Pérez B, et al. Efficacy of atomoxetine for the treatment of ADHD symptoms in patients with pervasive developmental disorders. J Atten Disord. 2013;17(6):497–505.
   PubMed Web of Science ®Google Scholar
• Jou R, Handen B, Hardan A. Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2005;15(2):325–330.
   PubMed Web of Science ®Google Scholar
• Kilincaslan A, Mutluer T, Pasabeyoglu B, et al. Effects of atomoxetine in individuals with attention-deficit/hyperactivity disorder and low-functioning autism spectrum disorder. J Child Adolesc Psychopharmacol. 2016;26(9):798–806.
   PubMed Web of Science ®Google Scholar
• Mazzone L, Reale L, Mannino V, et al. Associated with decreased clinical response to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. CNS Drugs. 2011;25(6):503–509.
   PubMed Web of Science ®Google Scholar
• Ramos B, Stark D, Verduzco L, et al. 2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals. Learn Memory. 2006;13(6):770–776.
   PubMed Web of Science ®Google Scholar
• Agarwal V, Sitholey P, Kumar S, et al. Double-blind, placebo-controlled trial of clonidine in hyperactive children with mental retardation. Mental Retardation. 2001;39(4):259–267. .
   PubMedGoogle Scholar
• Posey D, Puntney J, Sasher T, et al. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol. 2004;14(2):233–241.
   PubMed Web of Science ®Google Scholar
• Capone G, Brecher L, Bay M. Guanfacine use in children with down syndrome and comorbid attention-deficit hyperactivity disorder (ADHD) with disruptive behaviors. J Child Neurol. 2016;31(8):957–964.
   PubMed Web of Science ®Google Scholar
• Handen B, Sahl R, Hardan A. Guanfacine in children with autism and/or intellectual disabilities. J Dev Behav Pediatr. 2008;29(4):303–308.
   PubMed Web of Science ®Google Scholar